RxDoctor Payments Data

Laura Bamford, MD

Internal Medicine · San Diego, CANPI 1750435996

Payments from drug & device makers

$26,145in general payments, 2019–2025

Across 130 payments — averaging $201.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$24K
  • Viiv Healthcare Company$761
  • Merck$673
  • Alkermes, Inc.$450
  • Johnson & Johnson$274
  • AbbVie$32
  • plus $16 from 1 others

What the payments were for

  • Consulting fees$3,53314%
  • Speaking & faculty fees$16,20062%
  • Travel & lodging$3,83815%
  • Food & beverage$2,57510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead60$23,940
Viiv Healthcare Company40$761
Merck10$673
Alkermes, Inc.2$450
Johnson & Johnson15$274
AbbVie2$32
Braeburn Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,145 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$22,195
Medicare patients
86
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala301$1,190,271
TivicayDolutegravir Sodium63$180,783
DescovyEmtricitabine/Tenofov Alafenam42$100,150
RukobiaFostemsavir Tromethamine12$99,376
GenvoyaElviteg/Cob/Emtri/Tenof Alafen20$87,948
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf15$70,098
PifeltroDoravirine25$53,337
DovatoDolutegravir Sodium/Lamivudine12$32,484
MounjaroTirzepatide28$27,422
PrezcobixDarunavir/Cobicistat12$27,208
TrulicityDulaglutide21$19,269
Maraviroc11$14,983
EliquisApixaban23$12,422
Spiriva RespimatTiotropium Bromide14$6,955
Testosterone28$5,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$23,940$1,378,369363 claims
Viiv Healthcare CompanyTivicay, Rukobia, Dovato$761$312,64387 claims
MerckPifeltro$673$53,33725 claims
Johnson & JohnsonPrezcobix$274$27,20812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →